Survival benefit of extracorporeal membrane oxygenation in severe COVID-19: a multi-centre-matched cohort study

Abstract

Purpose

Extracorporeal membrane oxygenation (ECMO) has become an established therapy for severe respiratory failure in coronavirus disease 2019 (COVID-19). The added benefit of receiving ECMO in COVID-19 remains uncertain. The aim of this study is to analyse the impact of receiving ECMO at specialist centres on hospital mortality.

Methods

A multi-centre retrospective study was conducted in COVID-19 patients from 111 hospitals, referred to two specialist ECMO centres in the United Kingdom (UK) (March 2020 to February 2021). Detailed covariate data were contemporaneously curated from electronic referral systems. We analysed added benefit of ECMO treatment in specialist centres using propensity score matching techniques.

Results

1363 patients, 243 receiving ECMO, were analysed. The best matching technique generated 209 matches, with a marginal odds ratio (OR) for mortality of 0.44 (95% CI 0.29–0.68, p < 0.001) and absolute mortality reduction of 18.2% (44% vs 25.8%, p < 0.001) for treatment with ECMO in a specialist centre.

Conclusion

We found ECMO provided at specialist centres conferred significant survival benefit. Where resources and specialism allow, ECMO should be widely offered.

Supplementary Information

The online version contains supplementary material available at 10.1007/s00134-022-06645-w.

Take-home message

Extracorporeal membrane oxygenation (ECMO) has been used widely throughout the coronavirus disease 2019 (COVID-19) pandemic, however, conflicting outcomes have been reported. We found that in a well-matched cohort of ECMO-referred patients, retrieval on mobile ECMO to a specialist center conferred survival benefit.

Introduction

Extracorporeal membrane oxygenation (ECMO) has become a widespread therapy for severe respiratory failure (SRF) in coronavirus disease 2019 (COVID-19). While some reports indicate high mortality amongst COVID-19 patients receiving ECMO [1–4], other studies describe improved outcomes [5, 6], with a recent review reporting a 37.1% pooled in-hospital mortality [7]—comparable to pandemic influenza and non-COVID-19 acute respiratory distress syndromes [8]. Consensus guidelines have given cautious recommendation for ECMO in selected COVID-19 patients [9, 10]. Limited evidence from causal analyses in cohorts of COVID-19 ECMO patients [11, 12] suggests ECMO confers a survival benefit. However, given varied selection criteria, outcomes, and baseline characteristics [7, 13], the added benefit of ECMO in the COVID-19 SRF population remains uncertain.

A centralised national referral system was established at the start of the pandemic, providing a unified pathway for hospitals in the United Kingdom (UK) to refer patients for consideration of ECMO to specialist centres [14]. The high volume of referrals [15], and the detailed data recorded through the referral system, allow analysis of ECMO as an intervention in a large and well-characterized cohort of patients with COVID-19 SRF. In this study, we obtain a dataset of patients referred from 111 hospitals in the UK to two national ECMO centres, serving 24.5 million people in southern England and Wales. We perform a matching analysis to estimate the added survival benefit of receiving treatment via a specialist ECMO service, when compared to patients who received conventional therapy at their referring centre.

Methods

Study design and setting

A multi-centre retrospective cohort study was conducted in patients referred to two national ECMO centres [Guy’s and St Thomas’ Foundation Trust (GSTFT) and Royal Brompton and Harefield Trust (RBHT)] in the UK [16], between 3 March 2020 and 28 February 2021.

Following National Health Service commissioning in 2011, the UK patients with SRF may be referred to a designated ECMO centre, where specialists perform remote assessment, deliver advice, and consider patients against national eligibility criteria for retrieval on mobile ECMO. Criteria are outlined by NHS England (Supplementary Table A), establishing consistent indications for respiratory ECMO provision [17]. The primary indication is potentially reversible SRF (as indicated by severe hypoxaemia, Murray-score > 3, or uncompensated hypercapnia, in absence of significant frailty and organ failure severity).

Pathway changes took place at the start of the pandemic. Patient referrals were delivered through an online ‘Refer-a-patient’ portal (Bloomsbury Health, London, UK). Eligibility criteria were revised on 10 April 2020 to include consideration of respiratory ECMO survival prediction (RESP) score [14], and again in the latter half of the data collection period to include days of non-invasive ventilation (NIV) [14]. The pathway for COVID-19 ECMO provision has been previously described [6].

Patient selection

All referred patients with COVID-19 were eligible for inclusion. UK practice encourages active referral and discussion [6]. This approach includes patients when referring clinicians considered them to have COVID-19 SRF requiring specialist input. In a subset of patients referred twice (following closure of initial referral), the second referral instance was eligible for inclusion, as only the second could result in ECMO retrieval.

Patients referred with a non-COVID-19 diagnosis, or those referred for non-respiratory ECMO, were excluded. Patients with missing outcome data were excluded.

Study exposure

In the UK pandemic ECMO provision, referred and accepted patients are retrieved on mobile ECMO to a specialist centre (treatment group). Our exposure is therefore two-pronged, including provision of ECMO, and specialist SRF care in the centre itself. The control group contains patients whose referrals were not accepted, remaining in referring centres receiving conventional care.

This on-going practice of mobile ECMO retrieval has removed separation between transfer to specialist centres, and ECMO initiation, described in Peek et al. [18], where patients were transferred conventionally, with only a subset receiving ECMO.

Patient outcomes

Our primary outcome measure was in-hospital mortality during the same hospital episode as the referral. We treated inter-hospital transfers or repatriations as continuing the same hospital episode. There were no secondary outcome measures.

Data collection and curation

Demographic, clinical, and physiological parameters were submitted by the referring team at time of referral via the ‘Refer-a-patient’ system. Referral data were immediately reviewed by the designated ECMO centre, and following consideration, electronic responses were returned, documenting clinical decision (retrieve, manage at referring hospital, or perceived futility), and ECMO eligibility status by NHS criteria. A decision of ‘futility’ indicated an illness trajectory that was deemed to have limited reversibility with addition of ECMO. In the absence of validated scoring systems, these decisions were undertaken in discussion with specialists in referring and ECMO teams.

A bespoke data extraction pipeline was created in Python (Python Software Foundation, https://www.python.org/) to curate data into a structured database, ensure consistency and excluding erroneous values. Parallel manual cross-checking was employed to ensure data quality.

Outcome data were collected manually through direct contact with hospital audit, medical records, and clinical departments. Direct follow-up ensured mortality during the relevant hospital episode was identified.

Missing data handling

A subset of patient referrals was incomplete. We used random forest imputation [19] to handle missingness, subsequently testing this approach in sensitivity analysis.

Statistical analysis

We described the cohort across two pandemic waves, and separately examined referrals labelled ‘perceived futility’. The pandemic waves were defined as occurring before or after 1 August 2020. Continuous variables are presented with median and interquartile range and categorical with count and percentage. Between-groups comparisons are made using Mann–Whitney U for continuous and Pearson’s Chi-squared for categorical variables. A p value of < 0.05 was considered statistically significant.

Propensity score and matching

To measure the effect of our exposure on the primary outcome, we adopted propensity score (PS) matching. This enabled consideration of numerous covariates as contributors to confounding relative to number of events, and more granular exploration of matched and unmatched populations. Compared to multivariable analysis, matching accounts for changes in case characteristics and decision-making over time, by identifying comparable samples from observational real-world data [20].

To account for confounding from unmeasured discriminators of ‘too severe disease’ that would preclude ECMO, we excluded patients with a decision of ‘perceived futility’ from matching.

We additionally considered handling of patients labelled as ‘not meeting NHS criteria’. Changes to criteria occurred over the course of the pandemic (see “Study design”), and application of criteria required use of expert clinical judgement in deciding eligibility. Once patients labelled with ‘futility’ were excluded from the ‘not meeting NHS criteria’ group, the remainder contained many marginal cases, and the label was not felt to confer clear properties that might confound matching. We included this group for the main analysis, and tested assumptions in sensitivity analysis.

PS for treatment with ECMO was constructed using multivariable logistic regression. Covariates for PS generation (Supplementary Table F) were chosen based on their consideration in decision-making, and representation of severity.

Patients retrieved on mobile ECMO were matched with referred patients managed conventionally at referring centres. Three different matching techniques were evaluated: nearest neighbour calliper matching, genetic matching (GenMatch) [21], and optimal pair matching. A calliper width of 0.1 standard deviations of the logit of the PS was used for nearest neighbour and GenMatch. All matching was conducted in a 1:1 ratio without replacement. Balance between groups was assessed using standardised mean difference (SMD), with a SMD of < 0.1 indicating good balance [22].

The marginal odds ratio (OR) for hospital mortality with ECMO in the matched cohorts was estimated using univariable logistic regression. Bias-corrected confidence intervals were calculated using bootstrapping (4999 replications). The E value for each OR estimate of treatment effect was calculated to estimate unmeasured confounding [23, 24].

Statistical analysis and matching procedures were performed using R 4.0.3 (R Core Team, 2018) and the Matchit package [25].

Sensitivity analyses

Sensitivity analysis of PS matching was performed by (1) restricting eligible patients to those documented as ‘meeting NHS criteria’; (2) restricting population to patients with < 10% missing data. The matching procedure which generated the best combination of matches and covariate balance was used.

Ethics and approval

This study qualified as a service evaluation, as defined by the UK Health Research Authority, with waiver of individual informed consent. Data collection and analysis were carried out under evaluation for national ECMO commissioning.

Results

Patient characteristics

During the study period, 1580 patients with COVID-19 SRF were referred from 111 hospitals. Following exclusions, final analysis included 1363 patients, of which 243 were transferred to an SRF centre on mobile ECMO for continued treatment. Figure 1 shows a flow chart of patient inclusion. All patients in the treatment group received veno-venous (vv) ECMO (vv-ECMO). Referrals and outcomes over time are shown in Fig. 2. Prior to imputation, the dataset exhibited 11.1% missingness (Supplementary Table B, Supplementary Figure A).

Fig. 1.

Flow chart of patient inclusion, exclusion and sensitivity analyses

Fig. 2.

Histogram of referrals for consideration of ECMO grouped by 7-day period with treatment and outcome shown

Characteristics of the overall population and comparison based on referral decision are presented in Table 1. 430 (31.5%) patients had ‘perceived futility’ documented and were excluded from matching analysis. Compared to included patients, this group was older, with more severe organ failure, was hospitalised and ventilated for longer, and more likely to die (73% vs 43.2%, p < 0.001).

Table 1.

Characteristics, decision and outcomes of COVID-19 patients referred for ECMO

	All referrals (n = 1383)	Included for matching (n = 933)	‘Perceived futility’ (n = 430)	p-value
Demographics
Age	53 [45, 60]	51 [43, 58]	58 [52, 63]	< 0.001
Male sex	941 (69)	641 (68.7)	300 (69.8)	0.74
Body mass index (kg/m2)	31.01 [27.02, 35.46]	31.35 [27.34, 35.64]	29.88 [26.31, 34.64]	0.002
Clinical frailty scale	2 [2, 2]	2 [2, 2]	2 [2, 2]	< 0.001
Immunocompromised	82 (6)	40 (4.3)	42 (9.8)	< 0.001
Pre-referral admission characteristics
Hospital duration prior to IMV (days)	5 [2, 8]	4.5 [2, 7.92]	6.52 [3, 9.38]	< 0.001
IMV durationa (days)	3.15 [1, 6]	3 [1, 6]	4 [2, 9]	< 0.001
Cardiac arrest	43 (3.2)	24 (2.6)	19 (4.4)	0.1
Therapeutic interventions
Non-invasive ventilationb prior to IMV	921 (67.6)	612 (65.6)	309 (71.9)	0.025
Corticosteroids	910 (66.8)	606 (65)	304 (70.7)	0.042
Interleukin-6 inhibitor	117 (8.6)	77 (8.3)	40 (9.3)	0.59
Neuromuscular blockade	1178 (86.4)	803 (86.1)	375 (87.2)	0.626
Prone position trial	1054 (77.3)	712 (76.3)	342 (79.5)	0.211
Inhaled nitric oxide use	168 (12.3)	98 (10.5)	70 (16.3)	0.003
Chest drain(s) for pneumothorax	83 (6.1)	55 (5.9)	28 (6.5)	0.749
Renal replacement therapy	135 (9.9)	63 (6.8)	72 (16.7)	< 0.001
Noradrenaline dose (mcg/kg)	0.04 [0, 0.12]	0.03 [0, 0.1]	0.06 [0.01, 0.19]	< 0.001
Anticoagulation				< 0.001
Contraindicated	11 (0.8)	7 (0.8)	4 (0.9)
Prophylactic	883 (64.8)	647 (69.3)	236 (54.9)
Therapeutic	469 (34.4)	279 (29.9)	190 (44.2)
Respiratory parameters at time of referral
P/F ratio (mmHg)	78.33 [64.7, 97.78]	80 [67.28, 100.5]	73.93 [61.5, 91.67]	< 0.001
Static compliance (mL/cmH2O)	28.87 [20.89, 35.71]	30 [22, 37]	26.4 [19.44, 33.72]	< 0.001
Vt/PBW (mL/kg)	6.7 [5.98, 7.87]	6.74 [6.06, 7.99]	6.55 [5.78, 7.61]	0.001
Driving pressure (cmH2O)	16 [13, 20]	15.7 [13, 19]	17 [14, 22]	< 0.001
Plateau pressure (cmH2O)	29 [25, 31]	29 [25, 31]	29 [25, 32]	0.065
Positive end expiratory pressure (cmH2O)	12 [10, 14]	12 [10, 14.2]	12 [10, 14]	0.218
Minute ventilation (L/min)	9.84 [8, 11.52]	9.88 [8.04, 11.5]	9.65 [7.92, 11.63]	0.715
Arterial blood gas parameters at time of referral
pH	7.31 [7.24, 7.38]	7.32 [7.25, 7.39]	7.29 [7.2, 7.36]	< 0.001
pCO2 (mmHg)	59.62 [50.25, 71.03]	58.12 [49.2, 68.55]	63.9 [53.25, 77.25]	< 0.001
Bicarbonate (mmol/L)	27.02 [24, 31.45]	26.98 [24.08, 30.75]	27.6 [24, 32.6]	0.066
Base excess (mmol/L)	3.73 [1.8, 7.8]	3.6 [1.8, 7.4]	4.05 [1.8, 8.4]	0.219
Lactate (mmol/L)	1.3 [1, 1.8]	1.3 [1, 1.7]	1.4 [1, 1.8]	0.111
Laboratory parameters at time of referral
Haemoglobin (g/L)	113.55 [98, 126]	115 [101, 127]	108.5 [92, 124]	< 0.001
White cell count (10ˆ9/L)	12.04 [9.31, 15.55]	11.86 [9.2, 15]	12.91 [9.8, 16.88]	0.001
Platelets (10ˆ9/L)	272.1 [229, 319.91]	278.17 [235, 325]	263.78 [218.14, 307.27]	< 0.001
Creatinine (μmol/L)	73 [56, 99.63]	71 [55, 93]	79 [59.25, 117.5]	< 0.001
C-reactive protein (mg/L)	165.63 [76.5, 270.1]	170 [80, 274]	148.47 [68, 260]	0.1
Severity and risk scores
RESP score	4 [2.13, 5]	5 [3, 5]	3 [1, 4]	< 0.001
SOFA score	5.90 [4, 8]	5 [4, 7]	7 [4, 8]	< 0.001
Referral outcomes
Meets NHS criteria	608 (46.8)	463 (52.7)	145 (34.5)	< 0.001
Perceived futility	430 (31.5)	243 (26)	0 (0)	< 0.001
Treated with ECMO	243 (17.8)	403 (43.2)	314 (73)	< 0.001
Died	717 (52.6)	463 (52.7)	145 (34.5)	< 0.001

Values are expressed as median value [95% CI] or as n (%); p values for comparison statistics computed for ‘perceived futility’ vs other referral decision only

IMV invasive mechanical ventilation, P/F ratio partial pressure of arterial oxygen to fraction of inspired oxygen ratio, Vt tidal volume, PBW predicted body weight, RESP respiratory ECMO survival prediction, SOFA sequential organ failure assessment, NHS national health service

^aIMV duration includes all days of IMV, regardless of intensity

^bNIV use does not include high flow oxygen therapy

Comparisons between two COVID-19 waves are presented in Supplementary Tables C–E. Mortality for conventionally managed referrals increased in wave 2 (51.9% vs 62.4%, p = 0.001), but remained stable in ECMO-treated patients (22.9% vs 26.1%, p = 0.672). Wave 2 patients experienced shorter durations of hospitalisation and IMV prior to referral. They received more immunomodulation, less renal replacement therapy, more NIV, and developed greater barotrauma (with more chest drains). Overall, a greater proportion of patients with documented ‘perceived futility’ outcomes and a lower proportion of ECMO-treated patients were seen in wave 2.

Matching and treatment effect of ECMO

933 patients were available for matching. Nearest neighbour matching generated matches for 208 ECMO-treated patients, with a marginal OR for mortality of 0.47 (95% CI 0.32–0.73, p < 0.001, E value 2.28, E value lower CI 1.62) and absolute risk reduction (ARR) of 16.3% (42.3% vs 26%, p = 0.001) given ECMO treatment. GenMatch generated matches for 209 ECMO patients, with a marginal OR for mortality of 0.44 (95% CI 0.29–0.68, p < 0.001, E value 2.38, E value lower CI 1.72) and ARR of 18.2% (44% vs 25.8%, p < 0.001) given ECMO treatment. Optimal pair matching generated matches for 237 ECMO patients, with a marginal OR for mortality of 0.47 (95% CI 0.31–0.70, p < 0.001, E value 2.28, E value lower CI 1.68) and ARR of 16.5% (41.4% vs 24.9%, p < 0.001) given treatment with ECMO.

GenMatch matching resulted in the best combination of matches and covariate balance. Characteristics, outcomes, and standardised mean difference (SMD) of patients matched via this method are presented in Table 2. All covariates had a SMD ≤ 0.1 using GenMatch. The 34 ECMO-treated patients who were unable to be matched using this method were younger, had a shorter duration of IMV, were more hypoxic, had higher RESP scores, and received less corticosteroids (Table 3).

Table 2.

Characteristics and outcomes of conventionally and ECMO-treated patients before and after GenMatch matching, showing all co-variates used in matching procedure

	Before matching				After GenMatch matching
	Conventional (n = 690)	ECMO (n = 243)	SMD	p-value	Conventional (n = 209)	ECMO (n = 209)	SMD	p-value
Propensity score	0.14 [0.06, 0.3]	0.41 [0.27, 0.59]	1.13	< 0.001	0.37 [0.24, 0.49]	0.38 [0.24, 0.5]	0.03	0.733
Demographics
Age (years)	53 [45, 59]	46 [39, 52]	− 0.7	< 0.001	48 [39, 55]	46 [40, 53]	− 0.05	0.416
Male sex	474 (68.7)	167 (68.7)	0	1	146 (69.9)	144 (68.9)	− 0.02	0.915
BMI (kg/m2)	31.24 [27.04, 35.64]	31.67 [28.17, 35.76]	− 0.01	0.433	31.84 [27.76, 35.8]	31.64 [28.37, 35.92]	− 0.04	0.868
Clinical frailty scale	2 [2, 2]	2 [1, 2]	− 0.34	< 0.001	2 [1, 2]	2 [1, 2]	0.02	0.824
Immuno-compromised	35 (5.1)	5 (2.1)	− 0.21	0.07	4 (1.9)	4 (1.9)	0	1
Pre-referral admission characteristics
Hospital duration prior to IMV (days)	4.53 [1.7, 7.99]	4.16 [2, 7.2]	0.03	0.81	4.66 [2, 7.6]	4.11 [2, 7.27]	0.02	0.94
Duration of IMV (days)	3.16 [1, 6]	2 [1, 5]	− 0.48	< 0.001	2 [1, 4]	2 [1, 5]	0.1	0.239
Cardiac arrest	19 (2.8)	5 (2.1)	− 0.05	0.724	4 (1.9)	5 (2.4)	0.03	1
Therapeutic interventions
NIV	444 (64.3)	168 (69.1)	0.1	0.203	152 (72.7)	146 (69.9)	− 0.06	0.589
Corticosteroids	463 (67.1)	143 (58.8)	− 0.17	0.025	134 (64.1)	129 (61.7)	− 0.05	0.685
IL-6 inhibitor	61 (8.8)	16 (6.6)	− 0.09	0.335	11 (5.3)	15 (7.2)	0.08	0.543
Prone position trial	519 (75.2)	193 (79.4)	0.1	0.215	171 (81.8)	163 (78)	− 0.09	0.393
Chest drain(s) for pneumothorax	41 (5.9)	14 (5.8)	− 0.01	1	9 (4.3)	11 (5.3)	0.04	0.819
RRT	57 (8.3)	6 (2.5)	− 0.37	0.003	4 (1.9)	6 (2.9)	0.06	0.749
Anticoagulation				0.093				1
Contraindicated	7 (1)	0 (0)	− 0.12		0 (0)	0 (0)	0
Prophylactic	468 (67.8)	179 (73.7)	0.13		151 (72.2)	151 (72.2)	0
Therapeutic	215 (31.2)	64 (26.3)	− 0.11		58 (27.8)	58 (27.8)	0
Respiratory parameters at time of referral
P/F ratio (mmHg)	84 [69.98, 105.62]	71.55 [61.5, 83.7]	− 0.83	< 0.001	76.50 [63.44, 86.72]	72.53 [63, 85.61]	− 0.03	0.385
Static compliance (mL/cmH2O)	30 [22.11, 37.5]	29.36 [21.62, 34.71]	− 0.04	0.339	30 [21.86, 35.25]	29.23 [21.58, 35]	0.09	0.654
Driving pressure (cmH2O)	15.56 [13, 19]	16 [13, 20]	0.03	0.483	16 [14, 19.4]	16 [13, 20]	− 0.02	0.619
Plateau pressure (cmH2O)	29 [25, 31]	29 [25, 31.69]	0.03	0.617	29 [26, 31]	29 [25, 32]	− 0.05	0.843
Vt/PBW (mL/kg)	6.72 [6.01, 7.99]	6.79 [6.14, 7.88]	0.03	0.613	6.69 [6.14, 7.99]	6.73 [6.1, 7.85]	0	0.883
PEEP (cmH2O)	12 [10, 14.43]	12 [10, 14]	− 0.08	0.416	12 [10, 14.18]	12 [10, 14]	− 0.04	0.716
Minute ventilation (L/min)	9.85 [8, 11.51]	10 [8.13, 11.41]	0.06	0.707	9.91 [8.17, 11.58]	9.88 [8.1, 11.39]	− 0.01	0.62
Arterial blood gas parameters at time of referral
pH	7.32 [7.25, 7.39]	7.31 [7.25, 7.38]	− 0.1	0.288	7.31 [7.25, 7.39]	7.31 [7.24, 7.38]	− 0.08	0.962
pCO2 (mmHg)	58.2 [48.94, 68.33]	57.9 [49.88, 69]	0.06	0.527	58.5 [50.25, 68.33]	58.5 [50.4, 68.25]	0.07	0.732
Base excess (mmol/L)	3.7 [1.8, 7.77]	3.3 [1.65, 6.34]	− 0.18	0.157	3 [1.7, 6.3]	3.57 [1.7, 6.4]	0.01	0.349
Lactate (mmol/L)	1.3 [1, 1.7]	1.31 [1.1, 1.8]	0.04	0.209	1.3 [1, 1.6]	1.30 [1.1, 1.77]	0.08	0.177
Laboratory parameters at time of referral
White cell count (109/L)	11.68 [9, 15.08]	12 [9.71, 14.8]	0.02	0.498	11.70 [9.3, 14.8]	12 [9.7, 14.7]	0.08	0.68
Platelet count (109/L)	273.94 [228, 321.75]	283.91 [254.77, 332.16]	0.26	0.001	290 [249.34, 343.87]	283.91 [253, 331.59]	− 0.05	0.626
Haemoglobin (g/L)	115 [101, 126.96]	116 [101, 127]	0.07	0.539	119 [107, 129]	117 [101, 127]	− 0.06	0.256
C-reactive protein (mg/L)	159.4 [71, 262.85]	192 [104, 299.5]	0.23	0.001	170 [81, 280]	187 [101, 296.61]	0.08	0.314
Severity and risk scores
RESP score	4 [3, 5]	5 [4, 6]	0.81	< 0.001	5 [4, 6]	5 [4, 6]	− 0.09	0.175
SOFA score	5 [4, 7]	5 [4, 7.02]	− 0.02	0.363	4.96 [4, 7]	5 [4, 7.04]	0.08	0.427
Outcomes
Died	343 (49.7)	60 (24.7)		< 0.001	92 (44)	54 (25.8)		< 0.001

Values are expressed as median value [95% CI] or as n (%); BMI body mass index, IMV invasive mechanical ventilation, NIV non-invasive ventilation, RRT renal replacement therapy, P/F ratio partial pressure of arterial oxygen to fraction of inspired oxygen ratio, Vt tidal volume, PEEP positive end expiratory pressure, PBW predicted body weight, RESP respiratory ECMO survival prediction, SOFA sequential organ failure assessment

Table 3.

Comparison of matched (by GenMatch) and unmatched ECMO-treated patients

	Unmatched (n = 34)	Matched (n = 209)	p-value
Demographics
Age (years)	37 [34, 45.75]	46 [40, 53]	< 0.001
Male sex	23 (67.6)	144 (68.9)	1
Body mass index (kg/m2)	31.77 [26.84, 34.05]	31.64 [28.37, 35.92]	0.559
Clinical frailty scale	2 [1, 2]	2 [1, 2]	0.013
Immuno-compromised	1 (2.9)	4 (1.9)	1
Pre-referral admission characteristics
Hospital duration prior to IMV (days)	5 [2.76, 6.49]	4.11 [2, 7.27]	0.52
Duration of IMV (days)	1.5 [1, 3]	2 [1, 5]	0.021
Cardiac arrest	0 (0)	5 (2.4)	0.795
Therapeutic interventions
Non-invasive ventilation	22 (64.7)	146 (69.9)	0.687
Corticosteroids	14 (41.2)	129 (61.7)	0.038
Interleukin-6 inhibitor	1 (2.9)	15 (7.2)	0.582
Prone position trial	30 (88.2)	163 (78)	0.254
Chest drain(s) for pneumothorax	3 (8.8)	11 (5.3)	0.668
Renal replacement therapy	0 (0)	6 (2.9)	0.686
Anticoagulation			0.303
Contraindicated	0 (0)	0 (0)
Prophylactic	28 (82.4)	151 (72.2)
Therapeutic	6 (17.6)	58 (27.8)
Respiratory parameters at time of referral
P/F ratio (mmHg)	62.62 [57.36, 71.63]	72.53 [63, 85.61]	< 0.001
Static compliance (mL/cmH2O)	31.73 [25.18, 33.21]	29.23 [21.58, 35]	0.404
Driving pressure (cmH2O)	16 [14.18, 20]	16 [13, 20]	0.765
Plateau pressure (cmH2O)	28.5 [25.25, 30]	29 [25, 32]	0.414
Vt/PBW (mL/kg)	6.92 [6.56, 7.99]	6.73 [6.1, 7.85]	0.266
Positive end expiratory pressure (cmH2O)	11.96 [10, 14]	12 [10, 14]	0.213
Minute ventilation (L/min)	10.38 [9, 11.71]	9.88 [8.1, 11.39]	0.255
Arterial blood gas parameters at time of referral
pH	7.31 [7.25, 7.36]	7.31 [7.24, 7.38]	0.69
pCO2 (mmHg)	54.25 [47.46, 71.46]	58.5 [50.4, 68.25]	0.475
Base excess (mmol/L)	2.77 [1.39, 5.18]	3.57 [1.7, 6.4]	0.166
Lactate (mmol/L)	1.32 [1.07, 2.1]	1.3 [1.1, 1.77]	0.406
Laboratory parameters at time of referral
White cell count (109/L)	12 [9.74, 15.23]	12 [9.7, 14.7]	0.829
Platelet count (109/L)	285.78 [266.5, 363.49]	283.91 [253, 331.59]	0.515
Haemoglobin (g/L)	109.5 [100.25, 125.75]	117 [101, 127]	0.406
C-reactive protein (mg/L)	240.9 [152, 332.75]	187 [101, 296.61]	0.133
Severity and risk scores
RESP score	5 [5, 7]	5 [4, 6]	0.011
SOFA score	6.61 [4.08, 7]	5 [4, 7.04]	0.205
Outcomes
Died	6 (17.6)	54 (25.8)	0.416

Values are expressed as median value [95% CI] or as n (%); IMV invasive mechanical ventilation, P/F ratio partial pressure of arterial oxygen to fraction of inspired oxygen ratio, Vt tidal volume, PBW predicted body weight, RESP respiratory ECMO survival prediction, SOFA sequential organ failure assessment

Characteristics, outcomes, and balance metrics of patients matched via nearest neighbour and optimal pair matching are presented in Supplementary Tables G–I.

Sensitivity analysis

In sensitivity analysis of selection criteria, a subgroup with 463 patients were documented as ‘meeting NHS criteria’ for respiratory ECMO (220 conventional, 243 received ECMO). GenMatch generated 138 matches in this restricted cohort. The marginal OR for mortality was 0.52 (95% CI 0.32–0.89, p = 0.012, E value 2.12, E value lower CI 1.31) with an ARR of 14.5% (42% vs 27.5%, p = 0.016). Characteristics are shown in Supplementary Table J. Good balance was achieved with an SMD ≤ 0.1 for all covariates except for pH, which was slightly higher in the ECMO-treated cohort (SMD − 0.11).

In sensitivity analysis for missingness, a subgroup containing 550 patients remained (418 conventional, 132 ECMO) after exclusion for > 10% of missing data. Matches for 116 patients were generated using GenMatch, with marginal OR for mortality of 0.41 (95% CI 0.24–0.71, p = 0.002, E value 2.5, lower CI 1.66). Good balance was achieved with an SMD of ≤ 0.1 for all covariates. Characteristics shown in Supplementary Table K.

Discussion

The use of ECMO for COVID-19 SRF is supported by reports of safety and acceptable outcomes in retrospective cohorts [26], and more limited causal analysis in observational data. Our findings suggest that ECMO delivery at specialist SRF centres confers significant survival benefit, compared to matched patients who received conventional therapy in referring centres.

The considerable treatment effect (ARR 18.2%) produced in our study warrants closer examination. This effect was robust through different matching techniques and sensitivity analyses. For comparison, EOLIA [27] found an ARR of 11% between two arms, but was underpowered with substantial, late cross-over in the control group. Previous commentaries have noted that ARR would be greater if survival of cross-over patients was considered [28, 29]. The most comparable study from COVID-19 ECMO is Shaefi et al. [12], who adopted a multivariable adjustment approach, finding adjusted hazard ratio of 0.55 for death given ECMO (ARR 12.8%). In contrast, our results may represent added effect of treatment in a specialist SRF centre. Peek et al. [18] previously demonstrated ARR of 16% following transfer to a UK SRF centre, but with ECMO provided to only 76% of patients in the treatment group (as discussed, this separation is not present in standard UK ECMO pandemic pathways, where retrieval on mobile ECMO is usual practice).

Reported outcomes for COVID-19 ECMO remain varied. Recent examination of a large COVID-19 ECMO cohort [4] reported in-hospital mortality of 68%. Mortality in our study is considerably lower than Karagiannidis et al., and is also lower than that reported via international registries [26, 30] and previous non-COVID-19 trials [27]. The increase in ECMO mortality over time observed in other studies [30, 31] was also not seen in our cohort. Our population differs significantly from other published cohorts. First, while severity of respiratory failure was similar, it is likely that strict criteria enacted during the pandemic resulted in a more “well” population. Compared to published data, this is evidenced by younger age, shorter pre-ECMO ventilation, less renal support, lower SOFA, and higher RESP scores. Application of these criteria appeared consistent over time in our study, with clinical characteristics of ECMO patients remaining similar across waves (barring pre-ECMO therapeutic interventions). Second, all patients were retrieved on ECMO and treated in high-volume ECMO centres, which may associate with improved survival [26, 32]. These differences may highlight the impact of selective inclusion criteria, and centralised ECMO provisioning structures.

Neither our nor Shaefi et al.’s approach can negate effects of residual confounding. In considering unmeasured factors, it is notable that close matches were found from patients referred and considered for ECMO, but subsequently treated conventionally. Unmeasured features that may have influenced contemporaneous decision-making include views expressed over a telephone consult that are not reflected in available data. We note that characteristics and outcomes of referred patients changed over the course of our study period, and it is likely that understanding of patients thought to benefit from ECMO evolved over time. To challenge this, we restricted patient population in sensitivity analysis using human assigned labels (“met NHS criteria”), finding a reduced, but still considerable, ARR of 14.5%. The use of case-based matching also served to minimise temporal bias, with each case closely matched across clinical and physiological parameters. E values across our analyses suggest that substantial unmeasured confounding would be required to negate the observed treatment effect [23].

It is also important to acknowledge that realities of unprecedented pandemic demands may account for some of these close matches. It is reasonable to assume that some patients who could have benefited from ECMO may not have received it. The UK doubled its maximum ECMO capacity, indicative of significant system load, and it is conceivable that decision-making for cases with marginal or unclear benefit could have been influenced by factors related to resource availability at referring or receiving centre.

This study builds on previous studies of ECMO in H1N1 pandemic influenza [33, 34]. Our pool of eligible non-ECMO patients for matching was larger: n = 690 vs n = 195 (Noah et al.) and n = 157 (Pham et al.), resulting in more matches (n = 209 out of 243 eligible). Additionally, referrals recorded detailed pre-ECMO data; thus, matching was performed using variables that might represent heterogenous phenotypes [35, 36]. In designing this study, we address potential limitations discussed by Pham et al.: incorporation of rich covariates, reporting of matching procedures, use of stringent calliper width, and matching without replacement.

Our study presents several strengths, including use of rich covariate data to control most patient-centric factors. Our results remained robust through sensitivity analyses. ECMO patients were selected through the same nationally defined pathway and, outside of the concerns discussed, present a well-defined treatment group (previous study populations were treated in numerous centres with heterogeneous ECMO criteria). The use of data on which real-world decision-making took place adds pragmatism, and interpretability.

We also note important limitations. First, the possibility of residual confounding, which has been discussed. Second, pre-selection of patients via national referral criteria, and mixed exposure of both ECMO and SRF centre treatment, may limit generalisability to international cohorts where pathways differ. Third, we did not introduce measures of hospital-level strain or differences in conventional management, potentially resulting in exposure heterogeneity (i.e. transfer of patients from a ‘high strain’ hospital to a lower strain’ hospital or varying application of conventional management). However, analysis of UK hospital-level variation provides little evidence of differing strain between sites [37, 38] in context of nation-wide measures to ‘offload’ hospitals via patient transfer services [39]. Fourth, analysis is limited to in-hospital mortality, without examination of delayed out-of-hospital mortality, functional status of survivors or secondary complications on ECMO that may contribute to patient morbidity. Fifth, despite consistent results in sensitivity analysis for case-based data missingness, imputation of high missing for some variables (with assumption of missing-at-random) may reduce robustness. In summary, while similar outcomes were achieved across multiple analyses, results should be interpreted with caution.

Conclusion

Our study suggests that ECMO provided at specialist centres offers a survival benefit in selected patients with COVID-19 SRF, compared to similar patients treated with conventional therapy in their local hospital. Where resources and specialisation allow, ECMO should be offered in this critically unwell patient group. The subset of patients with severe COVID-19 who are likely to benefit most from ECMO remains unclear, and further work is required to determine factors which can assist in the decision-making process.

Supplementary Information

Below is the link to the electronic supplementary material.

Author contributions

SW and JZ were responsible for study conception and methodology. SW, JZ, RL and MB were responsible for data collection and cleaning. SW and JZ were responsible for analysis. All authors were responsible for manuscript writing and editing.

Declarations

Conflicts of interest

This study received no direct funding. JZ receives funding from the Wellcome Trust (203928/Z/16/Z) and acknowledges support from the National Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial College NHS Trust and Imperial College London. Other authors have no financial or non-financial competing interests to declare.

Ethical approval

This study qualified as a service evaluation, as defined by the UK Health Research Authority, with waiver of individual informed consent. Data collection and analysis were carried out under evaluation for national ECMO commissioning.